WBAG:TEVA

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Teva Pharmaceutical Industries

Executive Summary

Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, and internationally.


Snowflake Analysis

Fair value with moderate growth potential.


Similar Companies

Share Price & News

How has Teva Pharmaceutical Industries's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: TEVA's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

2.1%

TEVA

1.0%

AT Pharmaceuticals

4.1%

AT Market


1 Year Return

36.5%

TEVA

18.6%

AT Pharmaceuticals

-16.4%

AT Market

Return vs Industry: TEVA exceeded the Austrian Pharmaceuticals industry which returned 19.3% over the past year.

Return vs Market: TEVA exceeded the Austrian Market which returned -19.2% over the past year.


Shareholder returns

TEVAIndustryMarket
7 Day2.1%1.0%4.1%
30 Day13.9%2.0%7.3%
90 Day13.9%1.9%-10.0%
1 Year36.5%36.5%22.4%18.6%-15.4%-16.4%
3 Yearn/a27.0%12.3%-12.4%-19.1%
5 Yearn/a31.2%8.5%17.5%2.7%

Price Volatility Vs. Market

How volatile is Teva Pharmaceutical Industries's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is Teva Pharmaceutical Industries undervalued compared to its fair value and its price relative to the market?

>50%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: TEVA (€11.44) is trading below our estimate of fair value (€32.73)

Significantly Below Fair Value: TEVA is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: TEVA is unprofitable, so we can't compare its PE Ratio to the Pharmaceuticals industry average.

PE vs Market: TEVA is unprofitable, so we can't compare its PE Ratio to the Austrian market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate TEVA's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: TEVA is good value based on its PB Ratio (1.1x) compared to the XE Pharmaceuticals industry average (3.2x).


Next Steps

Future Growth

How is Teva Pharmaceutical Industries forecast to perform in the next 1 to 3 years based on estimates from 21 analysts?

65.1%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: TEVA is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (0.5%).

Earnings vs Market: TEVA is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: TEVA's is expected to become profitable in the next 3 years.

Revenue vs Market: TEVA's revenue (1.2% per year) is forecast to grow slower than the Austrian market (3.7% per year).

High Growth Revenue: TEVA's revenue (1.2% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: TEVA's Return on Equity is forecast to be low in 3 years time (18.6%).


Next Steps

Past Performance

How has Teva Pharmaceutical Industries performed over the past 5 years?

-37.5%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: TEVA is currently unprofitable.

Growing Profit Margin: TEVA is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: TEVA is unprofitable, and losses have increased over the past 5 years at a rate of -37.5% per year.

Accelerating Growth: Unable to compare TEVA's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: TEVA is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (5.5%).


Return on Equity

High ROE: TEVA has a negative Return on Equity (-6.03%), as it is currently unprofitable.


Next Steps

Financial Health

How is Teva Pharmaceutical Industries's financial position?


Financial Position Analysis

Short Term Liabilities: TEVA's short term assets ($12.9B) exceed its short term liabilities ($12.3B).

Long Term Liabilities: TEVA's short term assets ($12.9B) do not cover its long term liabilities ($28.4B).


Debt to Equity History and Analysis

Debt Level: TEVA's debt to equity ratio (178.1%) is considered high.

Reducing Debt: TEVA's debt to equity ratio has increased from 48.7% to 178.1% over the past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: Whilst unprofitable TEVA has sufficient cash runway for more than 3 years if it maintains its current positive free cash flow level.

Forecast Cash Runway: TEVA is unprofitable but has sufficient cash runway for more than 3 years, even with free cash flow being positive and shrinking by 25.1% per year.


Next Steps

Dividend

What is Teva Pharmaceutical Industries's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate TEVA's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate TEVA's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if TEVA's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if TEVA's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: TEVA is not paying a notable dividend for the Austrian market.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of TEVA's dividend in 3 years as they are not forecast to pay a notable one for the Austrian market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

2.6yrs

Average management tenure


CEO

Kåre Schultz (58yo)

2.58yrs

Tenure

US$11,596,564

Compensation

Mr. Kåre Schultz has been the Chief Executive Officer, President and Director of Teva Pharmaceutical Industries Limited since November 1, 2017. Mr. Schultz is a seasoned veteran in the healthcare industry  ...


CEO Compensation Analysis

Compensation vs Market: Kåre's total compensation ($USD11.60M) is above average for companies of similar size in the Austrian market ($USD3.95M).

Compensation vs Earnings: Kåre's compensation has been consistent with company performance over the past year.


Leadership Team

NamePositionTenureCompensationOwnership
Kåre Schultz
President2.58yrsUS$11.60m0.051% $6.5m
Eliyahu Kalif
Executive VP & CFO0.50yrUS$655.76kno data
Hafrun Fridriksdottir
Executive Vice President of Global R&D3.33yrsUS$4.38m0.0042% $537.4k
Brendan O'Grady
Executive Vice President of North America Commercial2.58yrsUS$3.46m0.0014% $175.7k
Gianfranco Nazzi
Executive Vice President of International Markets Commercial2.58yrsUS$3.45m0.0018% $233.8k
Eric Drapé
Executive Vice President of Global Operations0.67yrno data0.0020% $253.2k
Deborah Griffin
Senior VP & Chief Accounting Officerno datano datano data
Kevin Mannix
Senior Vice President of Investor Relationsno datano datano data
David Stark
Executive VP & Chief Legal Officer3.58yrsno data0.00027% $34.9k
Lori Queisser
Senior VP & Global Compliance Officer5yrsno datano data

2.6yrs

Average Tenure

52yo

Average Age

Experienced Management: TEVA's management team is considered experienced (2.6 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Kåre Schultz
President2.58yrsUS$11.60m0.051% $6.5m
Nechemia Peres
Independent Director2.92yrsUS$355.76kno data
Murray Goldberg
Independent Director2.92yrsUS$330.00kno data
Sol Barer
Independent Chairman of the Board3.33yrsUS$540.00k0.020% $2.6m
Amir Elstein
Independent Director11.42yrsUS$340.51k0.18% $23.6m
Gerald Lieberman
Independent Director4.75yrsUS$355.00k0.00094% $121.4k
Roberto Mignone
Independent Director2.92yrsUS$340.00kno data
Jean-Michel Halfon
Independent Director6yrsUS$320.45k0.00045% $58.1k
Rosemary Crane
Independent Director4.75yrsUS$330.00k0.00099% $127.9k
Perry Nisen
Independent Director2.92yrsUS$320.00kno data

3.1yrs

Average Tenure

63yo

Average Age

Experienced Board: TEVA's board of directors are considered experienced (3.1 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Teva Pharmaceutical Industries Limited's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Teva Pharmaceutical Industries Limited
  • Ticker: TEVA
  • Exchange: WBAG
  • Founded: 1901
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$14.373b
  • Listing Market Cap: US$12.917b
  • Shares outstanding: 1.10b
  • Website: https://www.tevapharm.com

Number of Employees


Location

  • Teva Pharmaceutical Industries Limited
  • 5 Basel Street
  • Petah Tikva
  • 4951033
  • Israel

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
TEVANYSE (New York Stock Exchange)YesSPON ADR EACH REP 1 ORD SHSUSUSDFeb 1982
TEVDB (Deutsche Boerse AG)YesSPON ADR EACH REP 1 ORD SHSDEEURFeb 1982
TEVA NBMV (Bolsa Mexicana de Valores)YesSPON ADR EACH REP 1 ORD SHSMXMXNFeb 1982
TEVASWX (SIX Swiss Exchange)YesSPON ADR EACH REP 1 ORD SHSCHCHFFeb 1982
0LERLSE (London Stock Exchange)YesSPON ADR EACH REP 1 ORD SHSGBUSDFeb 1982
TEVAWBAG (Wiener Boerse AG)YesSPON ADR EACH REP 1 ORD SHSATEURFeb 1982
TEVJ.FOTCPK (Pink Sheets LLC)Ordinary SharesUSUSDJun 1994
TEVATASE (The Tel-Aviv Stock Exchange)Ordinary SharesILILSJun 1994

Biography

Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, and internationally. The company offers sterile products, hormones, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments, and creams. It also develops, manufactures, and sells active pharmaceutical ingredients. In addition, the company provides specialty medicines for use in central nervous system and respiratory indications. Further, its products in the central nervous system and pain area comprise Copaxone for the treatment of relapsing forms of MS; AJOVY for the preventive treatment of migraine; and AUSTEDO for the treatment of tardive dyskinesia and chorea associated with Huntington disease. Additionally, the company’s products in the respiratory market include ProAir, ProAir Respiclick, QVAR, Duoresp Spiromax, Braltus, Cinqair/Cinqaero, and AirDuo RespiClick/ArmonAir RespiClick/AirDuo Digihaler for the treatment of asthma and chronic obstructive pulmonary disease, as well as Bendeka, Treanda, Granix, Trisenox, Lonquex, and Tevagrastim/Ratiograstim products in the oncology market. It has collaboration arrangements with Otsuka Pharmaceutical Co. Ltd. and Regeneron Pharmaceuticals, Inc. Teva Pharmaceutical Industries Limited was founded in 1901 and is headquartered in Petach Tikva, Israel. 


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/06/02 02:38
End of Day Share Price2020/05/29 00:00
Earnings2020/03/31
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.